Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial-Reference-Cited by-同舟云学术

Tafenoquine exposure assessment, safety, and relapse prevention efficacy in children with Plasmodium vivax malaria: open-label, single-arm, non-comparative, multicentre, pharmacokinetic bridging, phase 2 trial

Published:2022-02 Issue:2 Volume:6 Page:86-95
ISSN:2352-4642
Container-title:The Lancet Child & Adolescent Health
language:en
Short-container-title:The Lancet Child & Adolescent Health

Author:

Vélez Iván D,Hien Tran T,Green Justin A,Martin Ana,Sharma Hema,Rousell Victoria M,Breton John J,Ernest Terry B,Rolfe Katie,Taylor Maxine,Mohamed Khadeeja,Jones Siôn W,Chau Nguyen Hoang,Hoa Nhu Thi,Duparc Stephan,Tan Lionel K,Goyal Navin

Funder

Medicines for Malaria Venture

American Society of Tropical Medicine and Hygiene

GlaxoSmithKline

Publisher

Elsevier BV

Subject

Developmental and Educational Psychology,Pediatrics, Perinatology and Child Health

Reference24 articles.

1. Plasmodium vivax in the era of the shrinking P falciparum map;Price;Trends Parasitol,2020

2. Global epidemiology of Plasmodium vivax;Howes;Am J Trop Med Hyg,2016

3. Killing the hypnozoite—drug discovery approaches to prevent relapse in Plasmodium vivax;Campo;Pathog Glob Health,2015